SpringWorks Therapeutics Inc SWTX

NAS: SWTX | ISIN: US85205L1070 3/05/2024

45,11 USD (+4,06%)

(+4,06%) 3/05/2024

Grafiek SpringWorks Therapeutics Inc

Grafiek SpringWorks Therapeutics Inc

1 dag1d 4,06%
1 week1w -2,88%
1 maand1m 2,38%
3 maanden3m -8,07%
6 maanden6m 100,04%
1 jaar1j 91,23%
5 jaar5j 99,34%

SpringWorks Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

29 februari 2024 · SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors · Persbericht

1 november 2022 · Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma · Persbericht

25 februari 2021 · SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights · Persbericht

25 februari 2021 · SpringWorks Therapeutics Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update · Persbericht

22 februari 2021 · SpringWorks Therapeutics to Present at Upcoming Investor Conferences · Persbericht

4 februari 2021 · SpringWorks Therapeutics to Present at the Guggenheim Healthcare Talks 2021 Oncology Day · Persbericht

5 januari 2021 · SpringWorks Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference · Persbericht

Profiel SpringWorks Therapeutics Inc

Gezondheidstechnologie

Productie van biologische producten

Website: springworkstx.com

Hoofdzetel: Stamford, CT Verenigde Staten

CEO: Saqib Islam

Werknemers: 261

Aandelen SpringWorks Therapeutics Inc

Beurswaarde: 3,34 miljard USD

Effecten: 74,09 miljoen

Beta: 1,54

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe